Arcus Biosciences (RCUS) Misses Q3 EPS by 5c

Arcus Biosciences (NYSE: RCUS) reported Q3 EPS of ($1.11), $0.05 worse than the analyst estimate of ($1.06). Revenue for the quarter came in at $9.46 million versus the consensus estimate of $9.47 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• AI and earnings keep driving markets as focus shifts to Trump-Xi summit
• Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
• CRH plc (CRH) PT Lowered to $135 at UBS, Buy Rating Maintained